🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

64 results for “PTC” Clear

  1. A study to learn about the study medicine called PF-08046032 in people with advanced cancers.

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Advanced lymphomas (classic Hodgkin lymphoma [cHL], peripheral T cell lymphoma [PTCL], and diffuse large B cell lymphoma [DLBCL]), Solid tumors (eg, NSCLC, HNSCC, and melanoma)

    phase 1 other active

    1 trial

  2. An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma

    BioNTech Manufacturing GmbH

    Metastatic melanoma

    phase 1 other active

    1 trial

  3. Ataluren

    PTC THERAPEUTICS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

  4. Deflazacort

    PTC THERAPEUTICS, INC.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  5. Deflazacort

    PTC THERAPEUTICS, INC.

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  6. Deflazacort

    PTC THERAPEUTICS, INC.

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  7. Deflazacort and rifampin

    PTC THERAPEUTICS, INC.

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  8. PTC299

    PTC THERAPEUTICS, INC.

    Metastatic Breast Cancer

    phase 1 small molecule completed

    1 trial

  9. PTC299

    PTC THERAPEUTICS, INC.

    Leukemia, Myeloid, Acute

    phase 1 small molecule terminated

    1 trial

  10. PTC299

    PTC THERAPEUTICS, INC.

    Advanced Cancer

    phase 1 small molecule terminated

    1 trial

  11. PTC596

    PTC THERAPEUTICS, INC.

    High Grade Glioma

    phase 1 small molecule active

    1 trial

  12. PTC596

    PTC THERAPEUTICS, INC.

    Cancer

    phase 1 small molecule completed

    1 trial

  13. Unesbulin

    PTC THERAPEUTICS, INC.

    Ovarian Cancer

    phase 1 small molecule completed

    1 trial

  14. VEGF inhibitor PTC299

    PTC THERAPEUTICS, INC.

    Brain and Central Nervous System Tumors

    phase 1 small molecule completed

    1 trial

  15. Virus-specific T-cell Immunity for the Treatment of Some Resistant Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

    Istituto Gentili S.r.l.

    Patients who have received an allogeneic haematopoietic stem cell transplant and who have developed post-transplant viral reactivation (CMV, Adenovirus, EBV) resistant to pharmacological therapies.

    phase 1 other active

    1 trial

  16. A continuous intravenous infusion of 0.5-0.6 mg/kg/h Rocuronium Bromide Intravenous Solution (50 Mg/5 mL) to keep the target neuromuscular blockade (PTC = 1-2).

    First Tracks Biotherapeutics

    Neuromuscular Blockade

    small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources